Humanin attenuates apoptosis induced by DRPLA proteins with expanded polyglutamine stretches.
Kariya. Shingo S; Hirano. Makito M; Nagai. Yoshitaka Y; Furiya. Yoshiko Y; Fujikake. Nobuhiro N; Toda. Tatsushi T; Ueno. Satoshi S
Key Findings
- Humanin reduces cell death caused by expanded polyglutamine proteins in a cell model of DRPLA
- The protective effect of humanin is only partial, indicating other harmful pathways are involved
- Humanin also lowers the formation of protein aggregates associated with the disease
Practical Outcomes
- For biohackers, this research suggests humanin has some neuroprotective properties, but there’s no dosage, safety, or human data yet, so it can’t be turned into a reliable supplement or protocol for longevity or brain health at this time.
Summary
The study shows that the naturally occurring peptide humanin can partly protect nerve cells from dying when they contain harmful, expanded polyglutamine proteins linked to a rare brain disease, and it also reduces the clumping of these proteins, but the protection isn’t complete and the work was done only in lab-grown cells.
Abstract
Dentatorubral-pallidoluysian atrophy (DRPLA) is an autosomal-dominant neurodegenerative disorder caused by expansion of CAG repeats in the DRPLA gene, which codes for a polyglutamine (polyQ) stretch. The expanded polyQs are known to form intracellular aggregates and to confer neurotoxic activity. Recent studies have indicated that activation of apoptosis signal-regulating kinase 1 (ASK1) is involved in polyQ-induced apoptosis. Humanin (HN) is an endogenous peptide that inhibits neuronal cell death caused by mutant Alzheimer's disease genes, and this neuroprotective factor has recently been reported to suppress apoptosis by inhibiting activation of ASK1. To test the anti-ASK1 effect of HN on polyQ neurotoxicity, we constructed neuronal PC12 cells expressing expanded polyQs under the control of the Tet-Off system. Using this cell line, we showed that HN suppresses apoptotic cell death induced by expanded polyQs. However, the suppression was incomplete, suggesting that polyQs also stimulate other pathogenic cascades unrelated to ASK1. We further showed that HN suppresses polyQ aggregate formation. This result implied the possibility that aggregation is also related to the polyQ-mediated cascade involving ASK1 activation. Although the details remain uncertain, our results suggest that ASK1 is potentially involved in pathogenesis of DRPLA and that HN might contribute partially to the suppression of neurodegeneration in polyQ diseases.
Study Information
pubmed
2005
10.1385/jmn:25:2:165